Commentary on 'the DOPPS practice monitor for US dialysis care: Trends through April 2011': No surprises yet

American Journal of Kidney Diseases

Volumn 59, Issue 2, 2012, Pages 312-314

  Winkelmayer, Wolfgang C ^a   Weiner, Daniel E ^b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TUFTS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANEMIC AGENT; CALCIUM; HEMOGLOBIN; IRON; PARATHYROID HORMONE; PHOSPHORUS; VITAMIN D DERIVATIVE;

ANEMIA; BONE DEMINERALIZATION; CARDIOVASCULAR RISK; HEALTH CARE COST; HEALTH CARE QUALITY; HEALTH SERVICE; HEMODIALYSIS; HEMOGLOBIN BLOOD LEVEL; HUMAN; INFECTION; IRON THERAPY; KIDNEY FAILURE; LABORATORY TEST; MAINTENANCE THERAPY; MEDICAID; MEDICARE; NOTE; PATIENT MONITORING; PROSPECTIVE PAYMENT; REIMBURSEMENT; TREND STUDY;

EID: 84855860376     PISSN: 02726386     EISSN: 15236838     Source Type: Journal    
DOI: 10.1053/j.ajkd.2011.11.006     Document Type: Editorial

References (12)

1. Medicare Program; End-Stage Renal Disease Prospective Payment System. 42 CFR Part 410, 413 and 414. [CMS-1418-F] RIN 0938-AP57, Department of Health and Human Services, Centers for Medicare & Medicaid Services, pp 49030-49214.
2. W.C. Winkelmayer, G.M. Chertow The 2011 ESRD prospective payment system: an uncontrolled experiment Am J Kidney Dis 57 2011 542 546
3. US Government Accountability Office End-stage renal diseaseCMS should monitor access to and quality of dialysis care promptly after implementation of new bundled payment system (GAO-10-295) http://www.gao.gov/new.items/d10295.pdf March 2010 Accessed November 16, 2011
4. B. Robinson, D. Fuller, D. Zinsser The Dialysis Outcomes and Practice Patterns Study (DOPPS) Practice Monitor: rationale and methods for an initiative to monitor the new US bundled dialysis payment system Am J Kidney Dis 57 2011 822 831
5. A.K. Singh, L. Szczech, K.L. Tang Correction of anemia with epoetin alfa in chronic kidney disease N Engl J Med 355 2006 2085 2098 (Pubitemid 44749317)
6. T.B. Drueke, F. Locatelli, N. Clyne Normalization of hemoglobin level in patients with chronic kidney disease and anemia N Engl J Med 355 2006 2071 2084 (Pubitemid 44749316)
7. US Renal Data System USRDS 2011 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States Am J Kidney Dis 59 1(suppl 1) 2012 e1 e420
8. Medicare Program; End-Stage Renal Disease Quality Incentive Program. 42 CFR Part 413. [CMS-3206-F] RIN 0938-AP91, Department of Health and Human Services, Centers for Medicare & Medicaid Services, pp 628-646.
9. US Food and Drug Administration FDA Drug Safety Communication: modified dosing recommendations to improve the safe use of erythropoiesis-stimulating agents (ESAs) in chronic kidney disease http://www.fda.gov/Drugs/DrugSafety/ ucm259639.htm Accessed October 23, 2011
10. Medicare Program; Changes to the End-Stage Renal Disease Prospective Payment System for CY 2012, End-Stage Renal Disease Quality Incentive Program for PY 2013 and PY 2014; Ambulance Fee Schedule; and Durable Medical Equipment. 42 CFR Parts 413 and 414. [CMS-1577-P] RIN 0938AQ27, Department of Health and Human Services, Centers for Medicare & Medicaid Services, pp 40498-40550.
11. D. Joly, T.B. Drueke, C. Alberti Variation in serum and plasma PTH levels in second-generation assays in hemodialysis patients: a cross-sectional study Am J Kidney Dis 51 2008 987 995 (Pubitemid 351711603)
12. J.L. Roach, M.N. Turenne, R.A. Hirth, J.R. Wheeler, K.S. Sleeman, J.M. Messana Using race as a case-mix adjustment factor in a renal dialysis payment system: potential and pitfalls Am J Kidney Dis 56 2010 928 936